In metastatic breast cancer, the administration of bevacizumab to capecitabine has shown in a significant increase in response rates. The combination arm of bevacizumab plus capecitabine demonstrated a response rate of 19.8% compared to 9.1% in the capecitabine arm alone. However, the prolonged free survival or overall survival were comparable in both treatment arms. In a separate trial, the addition of bevacizumab to standard chemotherapy regimen (carboplatin and paclitaxel) in patients with advanced or relapsed non-small cell lung cancer demonstrate improved overall response and time to progression. In the bevacizumab plus standard chemotherapy, higher response rates (31.5% vs. 18.8%), longer median time to progression (7.4 vs. 4.2 months), and a modest increase in survival (17.7 vs. 14.9 months were found).